Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Jiaxin Niu"'
Autor:
Kiyotaka Yoh, Dusan Kotasek, David R. Spigel, Drew W. Rasco, Rachel Altura, Corinne Maurice-Dror, Dae Ho Lee, Martin Gutierrez, Byoung Chul Cho, Adnan Nagrial, Jiaxin Niu, Myung-Ju Ahn, Yixin Ren, Dong Wan Kim, S. Siddiqi, Jair Bar, Ruth Perets, Miyako Satouchi
Publikováno v:
Lung Cancer. 159:162-170
This first-in-human phase I study (NCT03179436) investigated anti-cytotoxic T-lymphocyte-associated protein 4 monoclonal antibody quavonlimab and anti-programmed death 1 monoclonal antibody pembrolizumab in patients with advanced solid tumors. The st
Autor:
Sophie Dalac-Rat, Anna Olsson-Brown, Jiaxin Niu, Praveen K. Bommareddy, Francesca Aroldi, Katy K. Tsai, Terence Duane Rhodes, Robert S. Coffin, Katharina C. Kähler, Adel Samson, Tawnya L. Bowles, Mohammed M. Milhem, Gino K. In, Bartosz Chmielowski, Eva Muñoz, Georgia M. Beasley, Joseph J. Sacco, Scott Baum, Kevin J. Harrington, Mark R. Middleton, Lavita Menezes, Hamid Emamekhoo, Jason Chesney, Andrea Pirzkall, Ari M. Vanderwalde
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundRP1 is an enhanced potency oncolytic HSV-1 which expresses a fusogenic glycoprotein (GALV-GP R-) and granulocyte macrophage colony stimulating factor (GM-CSF).1 In pre-clinical studies, RP1 demonstrated potent GALV-GP R-enhanced anti-tumor
Autor:
George J. Weiner, Heather Kelley, Geoffrey T. Gibney, Montaser Shaheen, Mohammed M. Milhem, Theresa Medina, Yousef Zakharia, Elizabeth I. Buchbinder, Luping Zhao, Jason J. Luke, John M. Kirkwood, Adil Daud, Diwakar Davar, James E. Wooldridge, Antoni Ribas, Jiaxin Niu, Anthony J. Olszanski, Dmitri Bobilev, Takami Sato, Hong Liu, Bartosz Chmielowski, Kim Margolin, Inderjit Mehmi, Arthur M. Krieg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundThere are limited therapeutic options for patients with progressive disease (PD) on or after PD-1–blocking antibody therapy. Vidutolimod (CMP-001) is a first-in-class, immunostimulatory virus-like particle containing a CpG-A Toll-like rec
Autor:
Jiaxin Niu, Yong Huang, Huiping Li, Lu Tan, Yue Zhang, Feng Xie, Hao Liao, Jianjun Yu, Xinyu Gui, Yaxin Liu, Nan Wang, Jiayang Zhang
Publikováno v:
Cancer Research. 81:PS16-08
Background: Genetic testing for patients with breast cancer (BCa) patients may change the routine patient care and shift the paradigm towards more personalized managing and treatment strategies. In particular, testing germline mutations in BRCA1/2 ha
Autor:
Scott T. Tagawa, Karl D. Lewis, Christine H. Chung, Himisha Beltran, Ricardo Valenzuela, Jiaxin Niu, Christine L. Hann, Andrew Eugene Hendifar, David S. Hong, Rahul Aggarwal, Aaron S. Mansfield, Michael Rossi, Anna F. Farago, Saiama N. Waqar, Carrianne Ludwig, Lowell B. Anthony, James M. Cleary, Matthew H. Taylor, Alan H. Bryce, Yan Luo
Publikováno v:
NPJ Precision Oncology
npj Precision Oncology, Vol 5, Iss 1, Pp 1-7 (2021)
npj Precision Oncology, Vol 5, Iss 1, Pp 1-7 (2021)
3552 Background: Delta-like 3 (DLL3) is highly and specifically expressed in solid tumors, such as neuroendocrine carcinomas (NECs), malignant melanoma (MM), and medullary thyroid carcinoma (MTC). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting
Publikováno v:
Current Oncology Reports. 23
Both anti-angiogenesis and immunotherapy are well-established therapeutic options in solid tumors. Here, we review the rationale as well as clinical evidence of combining these two approaches. There is strong rationale and substantial preclinical and
Autor:
Maura Gillison, Jiaxin Niu, Daniel Olson, Mark Stein, David Aggen, Utkarsh Acharya, Benjamin Creelan, Richard Hernandez, Jessica Price, Kevin J. Mancini, Louisa Dowal, James Foti, Vijetha Vemulapalli, Mara Shainheit, Masoud Golshadi, Raymond D. Stapleton, Jessica B. Flechtner, Thomas A. Davis
Publikováno v:
Cancer Research. 82:CT153-CT153
TiTAN™ is an open-label, multi-center Phase1/2a trial evaluating safety, tolerability, T-cell persistence and proliferation, and clinical activity in patients with some solid tumors. Adoptive T-cell therapies (ACT) have resulted in durable clinical
Autor:
Mohammed M. Milhem, Ari M. Vanderwalde, Tawnya Lynn Bowles, Joseph J. Sacco, Jiaxin Niu, Katy K. Tsai, Jason Alan Chesney, Bartosz Chmielowski, Adel Samson, Terence Duane Rhodes, Gino Kim In, Anna C. Pavlick, Trisha Michel Wise-Draper, Miguel F. Sanmamed, Praveen Bommareddy, Junhong Zhu, Robert S. Coffin, Kevin Joseph Harrington, Mark R. Middleton
Publikováno v:
Journal of Clinical Oncology. 40:9553-9553
9553 Background: RP1 is an enhanced potency oncolytic version of HSV1 that expresses human GM-CSF and the fusogenic protein GALV-GP R-. IGNYTE is a multicohort phase 1/2 study that evaluates the safety and efficacy of RP1 in combination with nivo (NC
Autor:
Jiaxin Niu, Cynthia A. Flannery, David W. Hall, Jess W. Hoag, Nishitha Therala, Ariane C. Kemkes, Josh Routh, Jean-Paul De La O, Lisa Macera, Snehal Govind Thakkar
Publikováno v:
Journal of Clinical Oncology. 40:9083-9083
9083 Background: Targeted therapy against unique molecular drivers has revolutionized non-small cell lung cancer (NSCLC) treatment. BRAF mutations, present in 2%-5%, have emerged as therapeutic targets, and can be divided into three classes: kinase-a
Autor:
Jiaxin Niu, Colette J. Shen, Tanguy Y. Seiwert, Jimmy J. Caudell, P. Said, Ari Rosenberg, J.M. Frakes, Jared Weiss, K. Jameson
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e361-e362
Purpose/Objective(s) Immune checkpoint inhibitors (ICIs) have led to improved treatment outcomes in a variety of cancers; however, the majority of patients exhibit resistance to ICIs. Overcoming this resistance is a major challenge in immune-oncology